<DOC>
<DOCNO>EP-0659181</DOCNO> 
<TEXT>
<INVENTION-TITLE>
SULFONAMIDE INHIBITORS OF HIV-ASPARTYL PROTEASE
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3142	A61K31403	A61K3855	A61K3140	C07D23100	C07D21300	C07K500	C07D21330	C07C31118	A61K31535	C07D20900	C07D26300	A61K31421	C07D23922	A61K31341	A61K3147	C07D21548	A61K314015	A61K31496	A61K31535	A61K3116	A61K314418	C07D20908	A61K3163	A61K3140	C07D20712	A61K3134	A61K3121	A61K3118	C07D41700	C07D30720	A61K315377	A61K31341	C07D20726	C07C30702	A61K314015	C07D30512	C07D29512	C07D27700	C07D41300	A61K3118	A61K3855	A61K31404	A61K3117	A61K3163	C07D40512	C07C31141	A61K3141	A61K314245	A61K3134	C07D40500	A61K31415	A61K314418	G01N33569	A61K3147	A61P3112	C07D27720	C07C30700	A61K31343	A61K31425	G01N33569	C07D20727	C07D23900	A61K31426	C07D30700	A61K314427	C07D40900	G01N3353	A61K315375	C07D26324	C07D30712	C07C31129	A61K3127	A61K31165	C07D41314	A61K31445	C07C31100	A61K314402	C07D27100	A61K3116	C07K5078	C07D20700	A61K3144	A61K3800	C07D40312	C07D40914	C07C31113	C07D20728	A61K31425	A61K31505	C07D41712	A61K3800	A61K3141	A61P3118	A61K31343	C07C30706	C07D30714	C07D30779	C07D30764	C07D27736	C07D40912	C07D41312	C07D23114	A61K31421	A61K314245	A61K31415	A61K31496	A61K31426	C07D20910	C07D27108	G01N3353	A61K31445	C07D40300	C07D30752	A61K3144	A61K314402	A61K315375	A61K31403	A61P3100	C07D29500	A61K31165	A61K31505	C07D30500	A61K3142	A61K3117	C07D21500	A61K314433	C07G9900	C07G9900	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61K	C07D	C07D	C07K	C07D	C07C	A61K	C07D	C07D	A61K	C07D	A61K	A61K	C07D	A61K	A61K	A61K	A61K	A61K	C07D	A61K	A61K	C07D	A61K	A61K	A61K	C07D	C07D	A61K	A61K	C07D	C07C	A61K	C07D	C07D	C07D	C07D	A61K	A61K	A61K	A61K	A61K	C07D	C07C	A61K	A61K	A61K	C07D	A61K	A61K	G01N	A61K	A61P	C07D	C07C	A61K	A61K	G01N	C07D	C07D	A61K	C07D	A61K	C07D	G01N	A61K	C07D	C07D	C07C	A61K	A61K	C07D	A61K	C07C	A61K	C07D	A61K	C07K	C07D	A61K	A61K	C07D	C07D	C07C	C07D	A61K	A61K	C07D	A61K	A61K	A61P	A61K	C07C	C07D	C07D	C07D	C07D	C07D	C07D	C07D	A61K	A61K	A61K	A61K	A61K	C07D	C07D	G01N	A61K	C07D	C07D	A61K	A61K	A61K	A61K	A61P	C07D	A61K	A61K	C07D	A61K	A61K	C07D	A61K	C07G	C07G	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61K38	A61K31	C07D231	C07D213	C07K5	C07D213	C07C311	A61K31	C07D209	C07D263	A61K31	C07D239	A61K31	A61K31	C07D215	A61K31	A61K31	A61K31	A61K31	A61K31	C07D209	A61K31	A61K31	C07D207	A61K31	A61K31	A61K31	C07D417	C07D307	A61K31	A61K31	C07D207	C07C307	A61K31	C07D305	C07D295	C07D277	C07D413	A61K31	A61K38	A61K31	A61K31	A61K31	C07D405	C07C311	A61K31	A61K31	A61K31	C07D405	A61K31	A61K31	G01N33	A61K31	A61P31	C07D277	C07C307	A61K31	A61K31	G01N33	C07D207	C07D239	A61K31	C07D307	A61K31	C07D409	G01N33	A61K31	C07D263	C07D307	C07C311	A61K31	A61K31	C07D413	A61K31	C07C311	A61K31	C07D271	A61K31	C07K5	C07D207	A61K31	A61K38	C07D403	C07D409	C07C311	C07D207	A61K31	A61K31	C07D417	A61K38	A61K31	A61P31	A61K31	C07C307	C07D307	C07D307	C07D307	C07D277	C07D409	C07D413	C07D231	A61K31	A61K31	A61K31	A61K31	A61K31	C07D209	C07D271	G01N33	A61K31	C07D403	C07D307	A61K31	A61K31	A61K31	A61K31	A61P31	C07D295	A61K31	A61K31	C07D305	A61K31	A61K31	C07D215	A61K31	C07G99	C07G99	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors, of formula (I). In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as antiviral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.
</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<DESCRIPTION>
The present invention relates to a novel
class of sulfonamides which are aspartyl protease
inhibitors. In one embodiment, this invention relates
to a novel class of HIV aspartyl protease inhibitors
characterized by specific structural and
physicochemical features. This invention also relates
to pharmaceutical compositions comprising these
compounds. The compounds and pharmaceutical
compositions of this invention are particularly well
suited for inhibiting HIV-1 and HIV-2 protease activity
and consequently, may be advantageously used as anti-viral
agents against the HIV-1 and HIV-2 viruses. This
invention also relates to methods for inhibiting the
activity of HIV aspartyl protease using the compounds
of this invention and methods for screening compounds
for anti-HIV activity.The human immunodeficiency virus ("HIV") is
the causative agent for acquired immunodeficiency
syndrome ("AIDS") a disease characterized by the
destruction of the immune system, particularly of CD4+
T-cells, with attendant susceptibility to opportunistic
infections -- and its precursor AIDS-related complex
("ARC") -- a syndrome characterized by symptoms such as 
persistent generalized lymphadenopathy, fever and
weight loss.As in the case of several other retroviruses,
HIV encodes the production of a protease which carries
out post-translational cleavage of precursor
polypeptides in a process necessary for the formation
of infectious virions (S. Crawford et al., "A Deletion
Mutation in the 5' Part of the pol Gene of Moloney
Murine Leukemia Virus Blocks Proteolytic Processing of
the gag and pol Polyproteins J.Virol., 53, p. 899
(1985)). These gene products include pol, which
encodes the virion RNA-dependent DNA polymerase
(reverse transcriptase), an endonuclease, HIV protease,
and gag, which encodes the core-proteins of the virion
(H. Toh et al., "Close Structural Resemblance Between
Putative Polymerase of a Drosophila Transposable
Genetic Element 17.6 and pol gene product of Moloney
Murine Leukemia Virus", EMBO J., 4, p. 1267 (1985);
L.H. Pearl et al., "A Structural Model for the
Retroviral Proteases", Nature, pp. 329-351 (1987); M.D.
Power et al., "Nucleotide Sequence of SRV-1, a Type D
Simian Acquired Immune Deficiency Syndrome Retrovirus",
Science, 231, p. 1567 (1986)).A number of synthetic anti-viral agents have
been designed to target various stages in the
replication cycle of HIV. These agents include
compounds which block viral binding to CD4+ T-
lymphocytes (for example, soluble CD4), and compounds
which interfere with viral
</DESCRIPTION>
<CLAIMS>
A compound selected from the group
consisting of:


(S)-N-1-(3-((3-Acetylamino-4-fluorobenzenesulfonyl)-benzyl-amino)-(1S,2
syn)-1-benzyl-2-hydroxy-propyl)-2-((quinoline-2-carbonyl)-amino)succinamide

and (S)-N-1-(3-((4-Acetylamino-3-fluorobenzenesulfonyl)-benzyl-amino)-(1S,2
syn)-1-benzyl-2-hydroxy-propyl)-2-((quinoline-2-carbonyl)-amino)succinamide;
(S)-N-1-(3-((5-Acetylamino-3-methyl-thiazole-2-sulfonyl)-benzyl-amino)-(1S,2
syn)-1-benzyl-2-hydroxypropyl)-2-((quinoline-2-carbonyl)-amino)-succinamide;
(S)-N-1-(1-Benzyl-3-(benzyl-(5-isoxazol-3-yl-thiophene-2-sulfonyl)-amino)-(1S,2
syn)-2-hydroxypropyl)-2-((quinoline-2-carbonyl)-amino)-succinamide;
(S)-N-1-(3-((Benzo(1,2,5)oxadiazole-4-sulfonyl)benzyl-amino)-(1S,2
syn)-1-benzyl-2-hydroxy-propyl)-2-((quinoline-2-carbonyl)-amino)-succinamide;
N-1-(1-(S)-Benzyl-3-(benzyl-(3-sulfamoylbenzenesulfonyl)-amino)-2-(syn)-hydroxy-propyl)-2-((quinoline-2-carbonyl)-amino)-succinamide;
(S)-N-1-(1-(S)-Benzyl-2-(syn)-hydroxyl-3-(isobutyl-(5-pyridin-2-yl-thiophene-2-sulfonyl)-amino)propyl)-2-((quinoline-2-carbonyl)-amino)-succinamide;
(S)-N-1-(3-((4-Benzenesulfonyl-thiophene-2-sulfonyl)-isobutyl-amino)-(1S,2
syn)-1-benzyl-2-hydroxy-propyl)-2-((quinoline-2-carbonyl)-amino)succinamide; 
(S)-N-1-(3-((4-Acetylamino-3-fluorobenzenesulfonyl)-isobutyl-amino)-(1S,2
syn)-1-benzyl-2-hydroxy-propyl)-2-((quinoline-2-carbonyl)-amino)succinamide;
(S)-N-1-(3-((3-Acetylamino-4-fluorobenzenesulfonyl)-isobutyl-amino)-(1S,2
syn)-1-benzyl-2-hydroxy-propyl)-2-((quinoline-2-carbonyl)-amino)succinamide;
(S)-N-1-(1-(S)-Benzyl-3-((4-acetylaminobenzenesulfonyl)-isobutyl-amino)-2-(syn)-hydroxypropyl)-2-((quinoline-2-carbonyl)-amino)-succinamide;
(S)-N-1-(3-((5-Acetylamino-3-methyl-thiazole-2-sulfonyl)-isobutyl-amino)-(1S,2
syn)-1-benzyl-2-hydroxy-propyl)-2-((quinoline-2-carbonyl)-amino)succinamide;
(S)-N-1-(3-((3-Acetylamino-benzenesulfonyl)isobutyl-amino)-(1S,2
syn)-1-benzyl-2-hydroxy-propyl)-2-((quinoline-2-carbonyl)-amino)-succinamide;
(S)-N-1-(3-((Benzo(1,2,5)oxadiazole-4-sulfonyl)isobutyl-amino)-(lS,2
syn)-1-benzyl-2-hydroxy-propyl)-2-((quinoline-2-carbonyl)-amino)-succinamide;
N-1-((1S-2 syn)-1-Benzyl-2-hydroxy-3-(1-isobutyl-3,3-dimethylsulfamide)-propyl)-2-((quinoline-2-carbonyl)-amino)-succinamide;
N-1-(3-((4-Acetylamino-benzenesulfonyl)-isobutylamino)-(1S,2
syn)-1-benzyl-2-hydroxy-propyl)-2-(pyridin-2-yl-methoxycarbonyl-amino)-3-S-methylbutyramide;
N-1-(3-((4-Acetylamino-benzenesulfonyl)-isobutylamino)-(1S,2
syn)-1-benzyl-2-hydroxy-propyl)-2-(pyridin-4-yl-methoxycarbonyl-amino)-3-S-methylbutyramide; 
N-1-(3-((4-Fluoro-benzenesulfonyl)-isobutylamino)-(1S,2
syn)-1-benzyl-2-hydroxy-propyl)-2-(pyridin-2-yl-methoxycarbonyl-amino)-3-S-methylbutyramide;
4-Fluoro-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-N-isobutyl-benzenesulfonamide;
3,4-Dichloro-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-N-isobutyl-benzenesulfonamide;
N-(4-(((2 syn,3S)-2-Hydroxy-4-phenyl-3-(pyridin-3-yl-methoxycarbonylamino)-butyl)-isobutyl-sulfamoyl)phenyl)-acetamide;
2,4-Dimethyl-thiazole-5-sulfonic acid-(1,1-dimethyl-ethoxycarbonylamino)-(2
syn,3S)-2-hydroxy-4-phenyl-butyl)-isobutyl-amide;
N-(4-(((2 syn,3S)-2-Hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-isobutylsulfamoyl)-phenyl)-acetamide;
4-Fluoro-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-((R)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-N-isobutyl-benzenesulfonamide
and 4-Fluoro-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-((R)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-N-isobutylbenzenesulfonamide;
Benzo(1,2,5)oxadiazole-5-sulfonic acid ((2
syn,3S)-2-hydroxy-4-phenyl-3-(pyridin-3-yl-methoxycarbonylamino)-butyl)-isobutylamide;
N-(4-(((2 syn,3S)-2-Hydroxy-4-phenyl-3-((R)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-isobutylsulfamoyl-phenyl)-acetamide
and N-(4-(((2 syn,3S)-2-Hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-isobutyl-sulfamoyl)-phenyl)acetamide; 
N-(2-Fluoro-5-(((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)isobutyl-sulfamoyl)-phenyl)-acetamide;
N-(3-(((2 syn,3S)-2-Hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-isobutylsulfamoyl)-phenyl)-acetamide;
4-Fluoro-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-((R)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-N-isobutyl-benzenesulfonamide;
N-(4-(((syn)-2-Hydroxy- (S)-4-phenyl-3-((tetrahydro-furan-(R)-3-yl)-oxycarbonylamino)-butyl)isobutyl-sulfamoyl)-phenyl)-acetamide;
4-Fluoro-N-(2 syn,3S)-2-hydroxy-4-phenyl-3-((tetrahydro-furan-(R)-3-ylmethoxycarbonylamino)butyl)-N-isobutyl-benzenesulfonamide
and 4-Fluoro-N-(2

syn,3S)-2-hydroxy-4-phenyl-3-((tetrahydro-furan-(S)-3-ylmethoxycarbonylamino)-butyl)-N-isobutylbenzenesulfonamide;
4-Chloro-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-isobutylbenzenesulfonamide;
N-((2 syn,3S)-2-Hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-N-isobutyl-4-methoxy-benzenesulfonamide;
4-Fluoro-N-(2-(syn)-hydroxy-3-((2-oxazolidon-(S)-4-yl)-methoxycarbonylamino)-4-(S)-phenyl-butyl)-N-isobutyl-benzenesulfonamide;
Benzene-1,3-disulfonic acid 1-amide 3-((2 syn,3S)-2-hydroxy-4-phenyl-3-(3-(S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-isobutyl-amide; 
Furan-3-sulfonic acid (2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)butyl)-isobutyl-amide;
N-((3-Allyloxycarbonylamino)-(2 syn,3S)-2-hydroxy-4-phenyl-butyl)-N-cyclopentylmethyl-4-fluorobenzenesulfonamide;
N-Cyclopentylmethyl-N-((3-ethoxycarbonylamino)-(2
syn,3S)-2-hydroxy-4-phenyl-butyl)-4-fluorobenzenesulfonamide;
4-Chloro-N-cyclopentylmethyl-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-benzenesulfonamide;
4-Chloro-N-cyclopentylmethyl-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-(pyridin-3yl-methoxycarbonyl)butyl)-benzenesulfonamide;
N-(4-(Cyclopentylmethyl-((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)butyl)-sulfamoyl)-phenyl)-acetamide;
3-Chloro-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-N-isobutyl-benzenesulfonamide;
4-Chloro-N-cyclopentylmethyl-N-(2-(syn)-hydroxy-3-((2-oxazolidon-4-(S)-yl-methyl)-oxycarbonylamino)-4-phenyl-butyl)-benzenesulfonamide;
N-cyclopentylmethyl-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)butyl)-4-methoxy-benzenesulfonamide;
N-((3-allyloxycarbonylamino)-(2 syn,3S)-2-hydroxy-4-phenyl-butyl)-N-cyclopentylmethyl-4-methoxybenzenesulfonamide;
N-Cyclopentylmethyl-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-(3-pyridin-3-yl-methoxycarbonylamino)-butyl-4-methoxy-benzenesulfonamide; 
Pyridine-3-sulfonic acid ((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)butyl)-isobutyl-amide,
trifluoroacetic acid salt ;
5-Isoxazol-3-yl-thiophene-2-sulfonic acid ((2
syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-isobutyl-amide;
N-(4-((3-(Allyloxycarbonylamino)-(2 syn,3S)-2-hydroxy-4-phenyl-butyl)-cyclopentylmethylsulfamoyl)phenyl)-acetamide;
N-(4-(Cyclopentylmethyl-((2 syn,3S)-2-hydroxy-4-phenyl-3-(pyridin-3-yl-methoxycarbonylamino)-butyl)sulfamoyl)-phenyl)-acetamide;
N-Cyclopentylmethyl-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)butyl)-benzenesulfonamide;
Pyridine-3-sulfonic acid cyclopentylmethyl-((2
syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-amide;
Piperidine-1-sulfonic acid ((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)butyl)-isobutyl-amide;
N-4-((2-(syn)-Hydroxy-3-((2-methoxymethylallyloxycarbonylamino)-4-(S)-phenyl-butyl)-isobutylsulfamoyl)-phenyl)-acetamide;
1-Acetyl-2,3-dihydro-1H-indole-6-sulfonic acid
((allyloxycarbonylamino)-(2 syn,3S)-2-hydroxy-4-phenylbutyl)-cyclopentylmethyl-amide;
1-Acetyl-2,3-dihydro-1H-indole-6-sulfonic acid
cyclopentylmethyl-((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)amide; 
N-Cyclohexylmethyl-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)butyl)-4-methoxy-benzenesulfonamide;
N-Cyclohexylmethyl-4-fluoro-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-benzenesulfonamide;
N-(4-(Cyclohexylmethyl)-((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)butyl)-sulfamoyl-phenyl)-acetamide;
N-((2 syn,3S)-2-Hydroxy-4-phenyl-3-((syn)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-N-isobutyl-4-methyl-benzenesulfonamide;
N-cyclopentylmethyl-4-hydroxy-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-
(pyridin-3-yl-methoxycarbonylamino)butyl)-benzenesulfonamide;
N-((2 syn,3S)-2-Hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-N-isobutyl-4-nitro-benzenesulfonamide;
4-Amino-N-((2 syn,3S)-2-Hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-N-isobutyl-benzenesulfonamide;
N-Cyclopentylmethyl-4-hydroxy-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-benzenesulfonamide;
N-Cyclopentylmethyl-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)butyl)-4-nitro-benezensulfonamide;
4-Amino-N-cyclopentylmethyl-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-benzenesulfonamide;
2,4-Diamino-N-cyclopentylmethyl-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-benzenesulfonamide; 
4-Hydroxy-N-(2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-N-isobutyl-benzenesulfonamide;
N-Cyclopentylmethyl-4-fluoro-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-benzenesulfonamide;
3,4-Dichloro-N-cyclopentylmethyl-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-benzenesulfonamide;
Benzyloxycarbonyl-(L)-isoleucine-N-(5-((3-amino-(2
syn,3S)-2-hydroxy-4-phenyl-butyl)-isobutyl-sulfamoyl)-2-fluoro-phenyl)-acetamide;

and
N-((2 syn,3S)-4-Cyclohexyl-2-hydroxy-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-N-cyclopentylmethyl-4-methoxy-benzenesulfonamide.
The compound according to claim 1, said
compound being selected from the group consisting of:


(S)-N-1-(1-(S)-Benzyl-2-(syn)-hydroxyl-3-(isobutyl-(5-pyridin-2-yl-thiophene-2-sulfonyl)-amino)propyl)-2-((quinoline-2-carbonyl)-amino)-succinamide;
(S)-N-1-(3-((4-Acetylamino-3-fluorobenzenesulfonyl)-isobutyl-amino)-(1S,2
syn)-1-benzyl-2-hydroxy-propyl)-2-((quinoline-2-carbonyl)-amino)succinamide;
(S)-N-1-(3-((Benzo(1,2,5) oxadiazole-4-sulfonyl)isobutyl-amino)-(1S,2
syn)-1-benzyl-2-hydroxy-propyl)-2-((quinoline-2-carbonyl)-amino)-succinamide;
N-1-((1S-2 syn)-1-Benzyl-2-hydroxy-3-(1-isobutyl-3,3-dimethylsulfamide)-propyl)-2-((quinoline-2-carbonyl)-amino)-succinamide; 
N-(4-(((2 syn,3S)-2-Hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-isobutylsulfamoyl)-phenyl)-acetamide;
N-((2 syn,3S)-2-Hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-N-isobutyl-4-methoxy-benzenesulfonamide;
4-chloro-N-cyclopentylmethyl-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-benzenesulfonamide;
N-Cyclopentylmethyl-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)butyl)-4-methoxy-benzenesulfonamide;
N-Cyclopentylmethyl-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-(3-pyridin-3-yl-methoxycarbonylamino)-butyl-4-methoxy-benzenesulfonamide;
N-Cyclopentylmethyl-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)butyl)-benzenesulfonamide;
N-Cyclohexylmethyl-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)butyl)-4-methoxy-benzenesulfonamide;
N-(4-(Cyclohexylmethyl)-((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)butyl)-sulfamoyl-phenyl)-acetamide;
N-cyclopentylmethyl-4-hydroxy-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-(pyridin-3-yl-methoxycarbonylamino)butyl)-benzenesulfonamide;
4-Amino-N-((2 syn,3S)-2-Hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-N-isobutyl-benzenesulfonamide;
4-Amino-N-cyclopentylmethyl-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-benzenesulfonamide; 
2,4-Diamino-N-cyclopentylmethyl-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-benzenesulfonamide;
4-Hydroxy-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-N-isobutyl-benzenesulfonamide;
and
N-((2 syn,3S)-4-Cyclohexyl-2-hydroxy-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-N-cyclopentylmethyl-4-methoxy-benzenesulfonamide.
The compound according to claim 2,
wherein said compound is 4-amino-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-N-isobutylbenzenesulfonamide.
A compound according to claim 3, for use
as a therapeutic agent.
A compound according to claim 3, for use
as a therapeutic agent when administered in combination

with at least one additional antiviral agent.
A compound according to claim 5 for use
as a therapeutic agent when administered in combination

with AZT.
A pharmaceutical composition comprising
4-amino-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-N-isobutyl-benzenesulfonamide

and a pharmaceutically
acceptable carrier, adjuvant or vehicle. 
The pharmaceutical composition according
to claim 7, further comprising at least one additional

antiviral agent.
The pharmaceutical composition according
to claim 8, wherein at least one additional agent is

AZT.
A use of the compound according to claim
3 in the preparation of a medicament for the treatment

or prophylaxis of an HIV infection.
The use according to claim 10, wherein
said HIV infection is HIV-1, HIV-2, or HTLV.
A method for the preparation of a
pharmaceutical composition for the treatment or

prophylaxis of an HIV infection which comprises mixing
a compound as defined in any of claims 1-3 with a

pharmaceutically acceptable carrier, adjuvant or
vehicle.
</CLAIMS>
</TEXT>
</DOC>
